MAGE A4-specific T cell receptor fusion protein

A TCR fusion protein with specific modifications and a glycosylation site at residue N18 enhances stability and binding affinity, effectively targeting and killing cancer cells expressing MAGE A4, addressing limitations in existing TCR fusion proteins.

JP2025527575APending Publication Date: 2025-08-22IMMUNOCORE LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2025509130
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-08-18
Filing Date
2023-08-17
Publication Date
2025-08-22

AI Technical Summary

Technical Problem

Existing TCR fusion proteins that bind to the MAGE A4 peptide:HLA complex lack favorable properties such as stability, binding affinity, cell killing potency, and in vivo pharmacokinetics, limiting their effectiveness in cancer immunotherapy.

Method used

A TCR fusion protein covalently linked to a T cell engaging domain and an antibody Fc domain, with specific amino acid substitutions and engineered cysteine residues, enhancing stability and binding affinity, and incorporating a glycosylation site at residue N18, to improve pharmacokinetics and cell killing potency.

Benefits of technology

The modified TCR fusion protein demonstrates improved stability, binding affinity, and enhanced in vivo persistence, effectively targeting and killing cancer cells expressing MAGE A4 with reduced off-target effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2025527575000001_ABST
    Figure 2025527575000001_ABST
Patent Text Reader

Abstract

The present disclosure provides a GVYDGREHTV (SEQ ID NO: 34) HLA-A antibody covalently linked to a T cell engaging domain and an antibody Fc domain that binds to a protein expressed on the cell surface of a T cell. * T cell receptor (TCR) fusion proteins containing a TCR that binds to the O2 complex, as well as related polynucleotides, vectors, kits, host cells, pharmaceutical compositions, methods, and uses, are provided. T cell receptors (TCRs) are naturally expressed by CD4+ and CD8+ T cells.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • T cell receptors

    US20190092834A1

  • Tumor antigens and CTL clones isolated by a novel procedure

    WO2000020445A2

  • T cell receptors

    WO2017175006A1